MedTrace Logo

Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C

NCT00298714 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2007-11-22

No results posted yet for this study

Summary

There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis.

The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).

Conditions

  • Chronic Hepatitis C
  • Liver Fibrosis

Interventions

DRUG

Losartan

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Pere Ginès, M.D. · Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona

  • Vicente Arroyo, M.D. · Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Completion
2006-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00298714 on ClinicalTrials.gov